Therapeutic combination comprising a Cdc7 inhibitor and an anti-neoplastic agent
The present invention provides a therapeutic combination comprising (a) a compound of formula (I) as set forth in the specification and (b) one or more antineoplastic agents selected from the group consisting of an alkylating or alkylating-like agent, an antimetabolite agent, a topoisomerase I inhibitor, a topoisomerase II inhibitor, an inhibitor of a growth factor or of a growth factor receptor, an antimitotic agent, a proteasome inhibitor, an inhibitor of an anti-apoptotic protein and an antibody directed against a cell surface protein, wherein the active ingredients are present in each case in lice form or in the form of a pharmaceutically acceptable salt or any hydrate thereof.
1. A therapeutic combination comprising (a) a compound of formula (I):
and (b) paclitaxel wherein (a) or (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof, wherein the ratio of (a) to (b) is selected from the group consisting of 12.5:1, 50:1 and 100:1.
2. The combination according to claim 1 which is a combined preparation for simultaneous, separate or sequential use.
3. A pharmaceutical composition comprising a combination according to claim 1 admixed with a pharmaceutically acceptable carrier, diluent or excipient.
4. A commercial package comprising, in a suitable container mean, (a) a compound of formula (I) as defined in claim 1 , and (b) paclitaxel wherein (a) or (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof, together with instructions for simultaneous, separate or sequential use thereof, wherein the ratio of (a) to (b) is selected from the group consisting of 12.5:1, 50:1 and 100:1.